Exchange: NASDAQ·Updated 07:00 AM EDT
CTMX logo

CTMX CytomX Therapeutics Inc

$3.68
$0.00
(0.00%)
Pre-Market
Prev Close $3.68
Reported EarningsAug 6
Mkt Cap$810.59M
Vol9.00

About CTMX

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
52

Neutral Sentiment

How do you feel about CTMX?

Advertisement|Remove ads.